Head-to-head · WeighScore
LVNG RX vs StackMD
The verdict
StackMD takes it — 63.4/100 to 62.5/100, but only just.
StackMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. StackMD is a New York telehealth platform (Medical 360 HC PLLC) selling compounded semaglutide and tirzepatide, both formulated with B12 and glycine, alongside NAD+, sermorelin and other longevity peptides. LVNG RX is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LVNG RX | StackMD |
|---|---|---|
| WeighScore | 62.5/100 | 63.4/100 |
| Grade | C | C |
| Scorecard rank | #272 | #259 |
| Semaglutide | $149/mo (starting dose, compounded) | $125/mo (1 mg dose, plus a separate fee, compounded) |
| Tirzepatide | $249/mo (microdose tier, starting dose, compounded) | $199/mo (5 mg dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #272 · C
Strengths
- One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
- States you are charged nothing if a provider does not approve you for treatment
- Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
- Semaglutide from $149/mo is competitive against the wider compounded market
- Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide
Where it loses points
- Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
- Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
- Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
- The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
- No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Graded #259 · C
Strengths
- Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
- Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
- No membership or platform fee — the medication price is the whole price
- States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility
Where it loses points
- All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
- Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
- Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
- Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
- Terms impose binding arbitration in New York and waive jury trial and class-action participation
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.